Immuno-Oncology | Specialty

MSI Testing's Impact on Immunotherapy in Gastric Cancers

December 22nd 2017

Immunotherapy in Advanced/Metastatic Gastric/GEJ Cancers

December 22nd 2017

Advanced/Metastatic Gastric Cancer: Beyond Frontline

December 22nd 2017

Treating Unresectable or Metastatic Gastric/GEJ Cancers

December 22nd 2017

Upfront Therapy Approaches in Gastric/GEJ Cancer

December 22nd 2017

Understanding Prognoses of Advanced Gastric/GEJ cancers

December 22nd 2017

The Molecular-Driven Classification of Gastric Cancers

December 22nd 2017

Classification Guidelines for Gastric/GEJ Cancers

December 22nd 2017

FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC

December 21st 2017

The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.

Dr. Sampath on Immunotherapy and Radiation Combinations in NSCLC

December 21st 2017

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses combinations of immunotherapy and radiation for the treatment of patients with non-small cell lung cancer (NSCLC).

Future of Bladder Cancer Likely to Be Combination Immunotherapy

December 21st 2017

Arjun Balar, MD, discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.

Immunotherapy and EGFR, ALK Inhibitors Deliver Precision Medicine in NSCLC

December 21st 2017

Edward S. Kim, MD, discusses the advancements in lung cancer in 2017, specifically in EGFR- and ALK-positive patients and those with PD-L1 expression.

Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

December 21st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

December 21st 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

FDA Approves Adjuvant Nivolumab for Melanoma

December 21st 2017

The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer

December 21st 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses PD-L1 as a biomarker in lung cancer.

Frontline Findings Put Fresh Focus on Immunotherapy in NSCLC

December 20th 2017

Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non

Pembrolizumab Investigated as Adjuvant RCC Therapy

December 18th 2017

Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.

Immunotherapy Resistance Remains a Puzzle

December 15th 2017

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Pembrolizumab Misses Endpoints in Phase III Gastric Cancer Trial

December 15th 2017

Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.